Thermo Fisher Scientific (NYSE:TMO) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Thermo Fisher Scientific (NYSE:TMO) had its target price increased by research analysts at Robert W. Baird from $723.00 to $756.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price would indicate a potential upside of 8.94% from the company’s current price.

A number of other research analysts have also recently issued reports on TMO. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada set a $740.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $664.33.

Thermo Fisher Scientific Trading Up 1.0%

Shares of TMO stock opened at $693.98 on Thursday. The stock’s fifty day moving average price is $642.42 and its two-hundred day moving average price is $552.67. The company has a market cap of $256.60 billion, a PE ratio of 37.33, a P/E/G ratio of 2.87 and a beta of 0.87. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $705.79. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the previous year, the firm earned $5.79 EPS. Thermo Fisher Scientific’s revenue was up 9.1% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last three months. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently modified their holdings of the business. Bank OZK bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $1,096,000. Ausdal Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth $456,000. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $15,501,867,000. German American Bancorp Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $4,920,000. Finally, Parallax Volatility Advisers L.P. purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at $814,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 results exceeded expectations. Thermo Fisher reported adjusted EPS of $6.68, above the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, surpassing estimates of approximately $11.95 billion. Adjusted EPS increased 15%, supported by stronger operating performance. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Organic growth and margins improved. Organic revenue growth reached 6%, with particularly solid demand in clinical research, bioproduction and electron microscopy. Operating margin expanded to 24.5%, aided by portfolio actions, acquisitions and productivity improvements. Thermo Fisher: You Don’t Need A Microscope To See The Growth Anymore
• Positive Sentiment: Management raised its outlook. Thermo Fisher lifted its full-year 2026 organic revenue-growth forecast to 4% and highlighted continued customer activity and confidence in sustained, multi-year expansion. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Early market reaction was volatile. Shares initially declined in premarket trading despite the earnings beat, suggesting that elevated expectations or profit-taking temporarily offset the favorable results before the stock reversed higher. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Unusual put-option activity signals near-term caution. Investors purchased 4,906 put options, about 52% above average daily volume, indicating some traders are hedging against volatility or a pullback following the earnings release.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.